BPTH - バイオパス・ホ―ルディングス (Bio-Path Holdings Inc.) バイオパス・ホ―ルディングス

 BPTHのチャート


 BPTHの企業情報

symbol BPTH
会社名 Bio-Path Holdings Inc. (バイオパス・ホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Bio-Path Holdings Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology DNAbilize is a platform that uses P-ethoxy a deoxyribonucleic acid backbone modification. Its lead drug candidate Liposomal Grb2 (BP1001) targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate Liposomal Bcl2 (BP1002) targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors including triple negative breast cancer and inflammatory breast cancer.   バイオパス・ホ―ルディングスは米国のバイオ医薬品企業の持株会社。子会社をとおして、主に癌治療候補剤リポソ―ムの開発を行う。急性骨髄性白血病、慢性骨髄性白血病、骨髄異形成症候群及び急性リンパ芽球性白血病を有する患者で臨床試験されている薬剤候補である。本社はテキサス州。  
本社所在地 4710 Bellaire Boulevard Suite 210 Bellaire TX 77401 USA
代表者氏名 Peter Henry Nielsen ピーターヘンリーニールセン
代表者役職名 Chairman of the Board President Chief Executive Officer Chief Financial Officer Treasurer
電話番号 +1 832-742-1357
設立年月日 36647
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 12人
url www.biopathholdings.com
nasdaq_url https://www.nasdaq.com/symbol/bpth
adr_tso
EBITDA EBITDA(百万ドル) -7.80800
終値(lastsale) 0.55
時価総額(marketcap) 7320408.15
時価総額 時価総額(百万ドル) 6.38485
売上高 売上高(百万ドル) 0.03700
企業価値(EV) 企業価値(EV)(百万ドル) 3.80685
当期純利益 当期純利益(百万ドル) -8.23400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Bio-Path Holdings Inc revenues was not reported. Net loss applicable to common stockholders increased 5% to $3.6M. Higher net loss reflects Change in fair value of warrant liabilit decrease from $2.4M (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.35 to -$0.32.

 BPTHのテクニカル分析


 BPTHのニュース

   HC Wainwright Cuts Bio-Path (NASDAQ:BPTH) Price Target to $10.00  2020/11/20 07:26:50 Transcript Daily
Bio-Path (NASDAQ:BPTH) had its price objective reduced by HC Wainwright from $12.00 to $10.00 in a research note published on Monday, AnalystRatings.net reports. They currently have a buy rating on the stock. Separately, Zacks Investment Research downgraded Bio-Path from a buy rating to a hold rating in a research note on Monday, October 19th. Shares […]
   Earnings Scheduled For November 13, 2020 - Stocks News Feed  2020/11/13 09:17:47 Stocks News Feed
Companies Reporting Before The Bell • Bio-Path Holdings (NASDAQ:BPTH) is expected to report earnings for its third quarter. • DraftKings (NASDAQ:DKNG) is expected to report quarterly loss at $0.61 per share on revenue of $131.75 million. • Digirad (NASDAQ:DRAD) is estimated to report quarterly earnings at $0.15 per share on revenue of $30.72 million. •… Read More »Earnings Scheduled For November 13, 2020
   Earnings Scheduled For November 13, 2020  2020/11/13 04:17:00 Benzinga
Companies Reporting Before The Bell • Bio-Path Holdings (NASDAQ:BPTH) is expected to report earnings for its third quarter. • DraftKings …
   Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020  2020/11/06 13:00:00 GlobeNewswire
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize®…
   Bio-Path (NASDAQ:BPTH) Trading Down 10.5%  2020/10/25 04:54:49 The Lincolnian
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares dropped 10.5% during trading on Friday . The company traded as low as $4.50 and last traded at $4.71. Approximately 1,635,579 shares were traded during mid-day trading, an increase of 348% from the average daily volume of 365,342 shares. The stock had previously closed at $5.26. BPTH has been the […]
   HC Wainwright Cuts Bio-Path (NASDAQ:BPTH) Price Target to $10.00  2020/11/20 07:26:50 Transcript Daily
Bio-Path (NASDAQ:BPTH) had its price objective reduced by HC Wainwright from $12.00 to $10.00 in a research note published on Monday, AnalystRatings.net reports. They currently have a buy rating on the stock. Separately, Zacks Investment Research downgraded Bio-Path from a buy rating to a hold rating in a research note on Monday, October 19th. Shares […]
   Earnings Scheduled For November 13, 2020 - Stocks News Feed  2020/11/13 09:17:47 Stocks News Feed
Companies Reporting Before The Bell • Bio-Path Holdings (NASDAQ:BPTH) is expected to report earnings for its third quarter. • DraftKings (NASDAQ:DKNG) is expected to report quarterly loss at $0.61 per share on revenue of $131.75 million. • Digirad (NASDAQ:DRAD) is estimated to report quarterly earnings at $0.15 per share on revenue of $30.72 million. •… Read More »Earnings Scheduled For November 13, 2020
   Earnings Scheduled For November 13, 2020  2020/11/13 04:17:00 Benzinga
Companies Reporting Before The Bell • Bio-Path Holdings (NASDAQ:BPTH) is expected to report earnings for its third quarter. • DraftKings …
   Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020  2020/11/06 13:00:00 GlobeNewswire
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize®…
   Bio-Path (NASDAQ:BPTH) Trading Down 10.5%  2020/10/25 04:54:49 The Lincolnian
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares dropped 10.5% during trading on Friday . The company traded as low as $4.50 and last traded at $4.71. Approximately 1,635,579 shares were traded during mid-day trading, an increase of 348% from the average daily volume of 365,342 shares. The stock had previously closed at $5.26. BPTH has been the […]
   HC Wainwright Cuts Bio-Path (NASDAQ:BPTH) Price Target to $10.00  2020/11/20 07:26:50 Transcript Daily
Bio-Path (NASDAQ:BPTH) had its price objective reduced by HC Wainwright from $12.00 to $10.00 in a research note published on Monday, AnalystRatings.net reports. They currently have a buy rating on the stock. Separately, Zacks Investment Research downgraded Bio-Path from a buy rating to a hold rating in a research note on Monday, October 19th. Shares […]
   Earnings Scheduled For November 13, 2020 - Stocks News Feed  2020/11/13 09:17:47 Stocks News Feed
Companies Reporting Before The Bell • Bio-Path Holdings (NASDAQ:BPTH) is expected to report earnings for its third quarter. • DraftKings (NASDAQ:DKNG) is expected to report quarterly loss at $0.61 per share on revenue of $131.75 million. • Digirad (NASDAQ:DRAD) is estimated to report quarterly earnings at $0.15 per share on revenue of $30.72 million. •… Read More »Earnings Scheduled For November 13, 2020
   Earnings Scheduled For November 13, 2020  2020/11/13 04:17:00 Benzinga
Companies Reporting Before The Bell • Bio-Path Holdings (NASDAQ:BPTH) is expected to report earnings for its third quarter. • DraftKings …
   Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020  2020/11/06 13:00:00 GlobeNewswire
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize®…
   Bio-Path (NASDAQ:BPTH) Trading Down 10.5%  2020/10/25 04:54:49 The Lincolnian
Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares dropped 10.5% during trading on Friday . The company traded as low as $4.50 and last traded at $4.71. Approximately 1,635,579 shares were traded during mid-day trading, an increase of 348% from the average daily volume of 365,342 shares. The stock had previously closed at $5.26. BPTH has been the […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 バイオパス・ホ―ルディングス BPTH Bio-Path Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)